EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.

ABSTRACT:

Background

Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there are some reports that some molecules are associated with cisplatin resistance in advanced BC, those reports have not been fully investigated. Therefore, we undertook a new search for cisplatin resistance-related genes targeted by tumor suppressive microRNAs as well as genes that were downregulated in cisplatin-resistant BC cells and clinical BC tissues.

Methods

First, we established cisplatin-resistant BOY and T24 BC cell lines (CDDP-R-BOY, CDDP-R-T24). Then, Next Generation Sequence analy

SUBMITTER: Okamura S 

PROVIDER: S-EPMC7798329 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature